Method: We reriewed the medical records of 3080 chronic stable angina patients who either underwent coronary artery bypass graft surgery (CABG) or percutaneous transhminal coronary angioplasty (PTCA) and determined the agreement between appropriateness ratings made by two expert physician panels, one from the United States and the second from The Netherlands. We also evaluated the agreement between these panels' appropriateness ratings and a decision analytic model's effectiveness categories.
INTRODUCTION
Practice guidelines have been proposed as a means to improve the quality of medical care, to reduce practice variations and to decrease health care expenditures. Over the past decade, thousands of guidelines have been produced by the health insurance industry, professional medical groups [1] , managed care organizations [2] and state and federal government [3, 4] . Ideally, these guidelines should be specific, clinically detailed and based on the results of randomized controlled trials. They should distinguish effective from non-effective care. In general, the results of only a limited number of randomized controlled trials are available to support the development of clinical guidelines. Therefore physicians and those paying for health care have come to rely on two other sets of methods, one predominantly qualitative and the second mainly quantitative, of evaluating and combining evidence from multiple studies in order to assess practice and generate guidelines. These two methods use distinct approaches in the way in which they seek to incorporate expert opinion in the guideline development process.
Some qualitative methods involve convening a panel of experts to develop practice recommendations. These recommendations have then been used as the basis of pre-and post-certification quality assurance efforts and as a tool to identify overuse and underuse of medical care provided by different hospitals and health care systems [5] [6] [7] . However, different panels, particularly those operating in distinct health systems and countries, may differ in their approach to how the clinical questions are defined and disagree in their conclusions.
Most quantitative analyses have used decision analytic techniques. The result is either a recommended treatment option or an estimated probability of an outcome from various treatment choices. In contrast to those using the more qualitative methods described above, decision analysts will usually not include expert opinions that have not been validated in the literature. While, in theory, an expert panel can choose to ignore the literature or interpret it in different ways in different situations, the goal of decision analysts is to be strictly evidence based. However, as currently practiced, expert panels do not base their recommendations solely on opinion and decision analysts frequently add expert opinion to their models.
The use of any of these methods as the basis for synthesizing evidence in order to distinguish effective from non-effective care requires that they be both valid and reliable. For example, to measure the reliability of 256 S. J. Bernstein et al. the expert panel process the assessments of several similarly conducted expert panels should be compared [8, 9] . The validity of these methods is more difficult to assess. Both expert panels and decision analytic techniques have content and face validity, but there is no gold standard or criterion against which to compare their recommendations. Any individual randomized controlled trial is too limited in scope, entry criteria, size and time to provide a single acceptable gold standard. However, the extent to which several different measures designed to assess effectiveness agree provides evidence supporting the construct validity of each of these measures. To the extent that they disagree we will remain unsure as to which method is actually measuring effectiveness, and applications of any particular one of these methods will result in a somewhat arbitrary assessment of what is effective and non-effective care.
To examine this issue, we studied the degree of overlap between two different sets of appropriateness criteria, one developed by a panel of U.S. physicians and the second by a panel of Dutch physicians, and a previously published decision analytic model for the use of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft surgery (CABG) in patients with chronic stable angina. These three examples were chosen because they were roughly concurrent and thus each attempted to synthesize the same body of evidence in the literature. We applied these criteria and the decision analytic model to chronic stable, angina patients referred for PTCA or CABG. Our objectives were to assess the degree to which the methods produce the same outcome (e.g. agree that the procedure should not have been done) and the clinical characteristics associated with disagreement
METHODS

Development of appropriateness criteria
We have described previously the methods by which we developed appropriateness scores for possible indications for the use of PTCA and CABG [5, 10, 11] . We reviewed the medical literature regarding the efficacy, effectiveness and risks of performing PTCA and CABG [12, 13] . From the literature reviews and discussions with clinicians, we developed mutually exclusive and comprehensive sets of indications for PTCA or CABG. The indications were intended to be sufficiently detailed so that performing the procedure would be equally appropriate or inappropriate for all patients with the same indication.
Using a modified Delphi technique, two expert panels of physicians who treat patients with coronary artery disease, one from the U.S.A. and the second from The Netherlands, independently rated the appropriateness of indications for coronary revascularization. The indications were organized into major clinical categories corresponding to the primary symptom or clinical reason that a patient might undergo revascularization (e.g. chronic stable angina). Within each clinical category, specific factors such as severity of angina and extent of angiographically demonstrated anatomic disease were used to define the indications.
The nine-member U.S. panel was nominated by medical specialty societies and was composed of two internists, one non-interventional cardiologist, three interventional cardiologists, and three cardiac surgeons. In 1990, they rated the appropriateness of 1007 indications for PTCA and 996 indications for CABG. The 12-member Dutch panel consisted of 6 interventional cardiologists and 6 cardiac surgeons, 1 from each of the 12 specialized heart centers permitted by the government to perform CABG and PTCA. In 1991, they rated 1040 PTCA indications and 982 CABG indications.
In brief, appropriateness was defined to mean that the expected health benefits (quality of life and/or longevity) exceeded the expected negative effects (morbidity and/or mortality) by a sufficient margin so that the procedure was worth doing. The method by which the panels were conducted, the way indications were classified with respect to appropriateness, and the definition of disagreement were similar [5, 10, 14] . Panelists rated the indications on a nine-point scale with 1 representing extreme inappropriateness and 9 extreme appropriateness. In traditional analyses of RAND appropriateness criteria procedures are classified as appropriate, uncertain or inappropriate. For this analysis, we combined uncertain cases with those rated appropriate. We made this decision in order to compare the appropriateness categories with effectiveness criteria (see below). Thus, indications were considered inappropriate if a panel's median score was from 1 to 3, and not inappropriate if the median score was from 4 to 9 or if there was disagreement among the panelists.
Development of effectiveness criteria
We used a previously developed decision analytic model by Wong et al. to estimate the prognosis of a cohort of patients with chronic stable angina and coronary artery disease anatomically amenable to revascularization by PTCA or CABG, who received one of three initial treatment strategies: PTCA, CABG or continued medical therapy [15, 16] . Patients were classified according to age, gender, coronary anatomy, left ventricular function, degree of angina, completeness of revascularization, and lesion type. Lesions were defined as Type A, B or C depending on a number of factors including their degree of accessibility, length, location in an angulated or non-angulated segment and presence of calcification. Type A lesions are minimally complex and associated with a higher PTCA success rate and lower complication rate than Type B lesions (moderately complex) or Type C lesions (severely complex). The morbidity and mortality associated with each procedure, the mortality associated with the underlying coronary artery disease, the benefits of revascularization, and the possibility of cross-over among treatment groups were also included in their model. The distribution of patients among the different health states was noted at the beginning of each year and the simulation continued until the entire cohort was dead. When there were no data from randomized controlled trials or the cohorts in such trials were too small to achieve statistically significant differences, Wong et al. used best judgment data to estimate outcome probabilities for their model. We used their calculated quality-adjusted life expectancy (QALE), which represents the effectiveness of the procedure (i.e. adjusting for survival, severity of symptoms, and shortterm morbidity from the procedure and myocardial infarction), to classify a procedure as effective (i.e. if its QALE exceeded that of medical therapy and was greater than or equal to that of the alternative invasive procedure) or not effective. We consider these categories to be analogous to the two appropriateness categories (i.e. not inappropriate and inappropriate) as both reflect an assessment of the health benefits relative to the risks of morbidity and mortality. This is the primary reason we did not combine cases judged uncertain by expert panel judgment with those judged inappropriate since we do not believe that an uncertain procedure is equivalent to one that is not effective.
We made three modifications to Wong's model. First, since we were interested in all chronic stable angina patients with coronary artery disease we expanded their analysis to include patients with left main disease and assumed that their benefit was at least as great as for patients with three-vessel disease involving the left anterior descending artery. Second, we assumed that patients with three-vessel disease undergoing PTCA received incomplete revascularization since that is the most common practice [15] [16] [17] . Third, Wong et al. calculated separate survival benefits for patients with Type A, Type B and Type C lesions, but since our data did not distinguish between Type A and Type B lesions we used the values for Type A stenoses.
Application of expert panel Judgments and decision analysis
We applied the appropriateness and effectiveness scores to patients representing the spectrum of patients who underwent PTCA or CABG in New York State and The Netherlands. We excluded patients who had previously undergone CABG or in whom CABG was to be combined with another procedure (e.g. valve surgery). In New York State we randomly selected 2644 patients who underwent coronary revascularization in 1990 [5, 10] . We then excluded all patients who did not present with chronic stable angina, leaving 519 PTCA patients and 617 CABG patients.
In The Netherlands we prospectively collected data on 3980 patients referred for consideration of coronary revascularization at 10 of the 12 heart centers, 5 from university and 5 from non-university hospitals in 1992.
For this report, we included all patients referred for coronary revascularization (n = 3207) who had chronic stable angina (n= 1945). There were 891 PTCA patients and 1053 CABG patients. In two of the centers 10-20% of the sample were missed due to data collection problems. This did not affect the outcomes of the analyses [17, 18] .
An abstraction form was created to collect the clinical and laboratory data needed to determine the appropriateness of revascularization in the sample patients. The data were collected by trained research assistants, nurses or physicians. Each abstract was then reviewed for completeness, accuracy and consistency before data entry [5, 17] .
Since we were interested in examining the level of agreement in the outcomes of the two methods when applied to a large population, we combined the New York State and Dutch samples into a single dataset of chronic stable angina patients referred for either PTCA or CABG. There were 1410 PTCA patients and 1670 CABG patients in our final sample.
Analysis
We assigned three ratings to each patient based on information abstracted from the medical record. One rating was assigned for the U.S. panel, a second rating assigned for the Dutch panel and a third rating corresponded to the decision analytic model. In accordance with the U.S. panel's decision two adjustments were made to their appropriateness ratings: (1) bypass surgery patients who were candidates for both CABG and PTCA and for whom the panel judged PTCA more appropriate were given a lower rating than would have applied for CABG if they had not been PTCA candidates (e.g. inappropriate if the CABG rating was not inappropriate when the patient was not a candidate for PTCA); and (2) angioplasty patients for whom the panel judged CABG more appropriate were given a lower rating than would have applied for PTCA compared with medical therapy (i.e. inappropriate if the PTCA rating was not inappropriate when PTCA was compared with medical therapy). Details on this process are reported elsewhere [5] .
The Dutch panel explicitly rated the appropriateness of each procedure compared with medical therapy and the appropriateness of the two procedures relative to each other (i.e. the appropriateness of CABG compared with PTCA). For this report, we have modified their ratings on the appropriateness of each procedure compared with medical therapy in a manner similar to that performed for the U.S. panels ratings. For the decision analytic model, we classified each case as either effective or not effective.
We analyzed the level of agreement in three ways. First, we examined the percentage of observed total agreement between the two panels' ratings (i.e. inappropriate and not inappropriate) and between each panel's rating and the corresponding finding of the decision analytic team (i.e. not effective and effective). Second, we used Cohen's K to assess the level of agreement after adjusting for agreement due to chance alone and compared results across each two-way combination of ratings. Finally, we calculated separate indices for the proportion of agreement on inappropriate cases (e.g. when the two panels both rated a case inappropriate -this is the equivalent of Feinstein's positive agreement) and the proportion of agreement on not inappropriate cases (e.g. when both panels rated a case not inappropriate -the equivalent of Feinstein's negative agreement) [19, 20] . Differences in distribution across multiple categories were tested using the Fisher's exact test for unweighted contingency tables.
RESULTS
Agreement on PTCA cases
There was 64% agreement between the U.S. and Dutch panels regarding the appropriateness of PTCA compared with the best alternative treatment (see Table  1 ). While the U.S. panel rated only 15 of the 1410 PTCA cases inappropriate (1.1%), the Dutch panel judged 517 PTCAs (37%) inappropriate (see Table 2 ). There was almost no agreement beyond chance between the two panel's appropriateness ratings (K = 0.03) and this was because the two panels had only 5% agreement on which cases were inappropriate. The U.S. panel's criteria and the decision analytic model's criteria agreed on 63% of the cases (K = 0). This was substantially less than the 92% agreement between the Dutch panel and the decision analytic model (K = 0.83). The poor correlation between the U.S. panel ratings and the findings of the decision analytic team was mainly due to their 2% 1 A clinical variable is used in the model (yes), not used in the model (no), or is used but several categories are merged (combined). For example, the decision analytic model divided patients into those with three-vessel disease with and without proximal left anterior descending artery (PLAD) involvement while the two expert panels combined these two categories and only considered if a patient had three-vessel disease without regard to PLAD involvement.
Left main coronary artery disease was not included in the original decision analytic model. We included it in this study by assigning the values for patients with three-vessel disease with PLAD involvement.
3 PLAD: proximal left anterior descending artery. 4 The risk model used by the decision analytic model was continuous while that used by the two panels was based on a summary score from either the Parsonnet [43] or O'Connor [44] indices and divided into two categories (Dutch panel) or three categories (U.S. panel). 5 The decision analytic model did not include exercise stress tests in its primary analysis. It was included in a sensitivity analysis in the original paper by Wong et al. [15] .
Agreement on CABG cases
For bypass surgery, there was 90% agreement between the U.S. and Dutch panels (K = 0.18) (see Table 1 We also examined the extent to which applying the U.S. panel criteria, Dutch panel criteria and the decision analytic model all agreed. For PTCA the overall simple agreement was 60% (K = 0.28), which was substantially less than the 87% agreement for CABG (K = 0.44).
DISCUSSION
There were two major findings from this study. First, there was substantial disagreement between appropriateness criteria developed by an expert panel of U.S. physicians and similar criteria developed by a Dutch expert physician panel and a decision analytic team for PTCA and some disagreement for bypass surgery. Although these criteria are primarily used to identify overuse of procedures, it is in precisely this task that we found disagreement. Second, there was excellent agreement between the Dutch expert panel and decision analytic team, despite the differences in the philosophy behind the two methods. The disagreement between the two panels' appropriateness ratings and between those of the U.S. panel and the decision analytic teams effectiveness ratings occurred despite the panelists' reviewing and discussing the same body of literature on these two procedures. There are several possible explanations for the disagreement.
First, we studied the data that were available to the panels and decision analytic team as they were developing their appropriateness and effectiveness criteria. By 1990, results from at least three major randomized controlled trials and other studies comparing the efficacy of bypass surgery and medical therapy had been published [21] [22] [23] [24] . However, at that time, no randomized controlled trials involving PTCA had been completed [25] . Thus there was limited data for decision making with respect to PTCA.
Next, we examined the clinical factors they considered important to include in their criteria (see Table 3 ). Common variables used by the three groups were severity of coronary artery disease, left ventricular function, angina class and risk for surgery. Although the three groups differed somewhat in the thresholds used to define these variables, little of the disagreement was attributable to these variations. Two other variables, the outcome of exercise stress tests [26] and the intensity of medical therapy, were considered by the panels but not by the decision analytic model in our analysis. Some cases judged inappropriate by the panels but effective by the decision analytic team involved patients who had either not undergone an exercise stress test or had a negative stress test while others involved patients who were on less than maximal medical therapy ( Table 4) .
The most important reason for disagreement was related to lesion type, a variable that was not specifically included by all three groups (see Table 4 ). The U.S. panel only included lesion type, defined as PTCA candidacy, in their appropriateness criteria for bypass surgery. We believe the reason for this difference was the quality of information known about lesion type when the criteria were developed. There were limited data regarding risks and outcomes for the different lesion types. When the American College of Cardiology and American Heart Association (ACC/AHA) Task Force on Percutaneous Transluminal Coronary Angioplasty examined this issue, they reported that the expected success rate of PTCA was lower and the complication rate higher in patients with Type C compared to Type A or B lesions based primarily on their expert opinion [26] , (King, S., personal communication). The expert panels and the decision analytic teams all agreed that there were few data on this topic (Leape, L. L., personal communication; Bernstein, S., unpublished data; Wong, J., personal communication). Subsequently, the decision analytic team used the ACC/ AHA task force estimates of procedural outcomes in 1 Indications reflect those clinical factors either included in the appropriateness ratings of the U.S. or Dutch expert panels or associated with disagreement between the expert panels and the decision analytic model.
2 CABG was rated inappropriate. 3 CABG was considered effective. 4 PTCA was rated inappropriate. 5 PTCA was considered effective. 6 The U.S. panel did not include lesion type in its appropriateness ratings; however, the decision analytic model did. The two panels differed in how they used lesion type. The Dutch panel included lesion type in their PTCA indications and their average appropriateness score for patients with a Type C lesion was three points lower (i.e. more inappropriate) than for patients with Type A or B lesions on the nine-point appropriateness scale [18] , In contrast, the U.S. panel decided not to include lesion type in their indication structure for rating the appropriateness of PTCA. This may seem counterintuitive, since the panels were instructed to balance benefit and risk which could be influenced by lesion type, but the U.S. panel's discussion provides insight into this decision. For bypass surgery, it decided that although the coronary anatomy was critical to the decision on whether to bypass a specific vessel (e.g. a cardiothoracic surgeon might elect not to revascularize a vessel with poor distal run-off) the appropriateness ratings should be based on the number of diseased vessels and left ventricular function and not on the suitability of the vessel for bypass treatment. Similarly, the panelists argued that although lesion type might influence whether a physician attempts to do angioplasty, decisions on appropriateness should also be made based on anatomy and left ventricular function and not lesion type (Leape, L. L., personal communication). Thus, if a physician attempted to do PTCA, the panel assumed that it was technically feasible regardless of lesion type (Leape, L. L., personal communication). Unfortunately, these insights are frequently not available to someone trying to apply expert panel ratings.
Since then new data have become available. Reports from eight randomized trials comparing the use of PTCA and bypass surgery in patients with angina have been published [27] [28] [29] [30] [31] [32] [33] [34] [35] and the results of a meta-analysis of these trials suggest similar survival outcomes for patients who are clinically and angiographically suitable for either procedure [36] . A new ACC/AHA Task Force report on PTCA has also been issued and lesion type is no longer used independently to predict the success of PTCA or the probability of complications [37] . Perhaps if this information had been known when the criteria were being established there would have been less disagreement.
A third possible explanation for the disagreement, from the point of view of a critic of the expert panel approach, is that panel judgments may primarily reflect group opinion that is not based on scientific fact [38] [39] [40] . This might lead to less evidence-based decision making when compared with decision analysis. Yet the Dutch panel and decision analytic team reached very high levels of agreement. So, disagreement with the decision analytic team is not necessarily a consequence of the panel process.
A fourth explanation for the discrepancies we observed may be related to the panel composition. The U.S. panel included primary care providers while the Dutch panel consisted only of specialists. Previous studies suggest that this might lead to higher ratings (i.e. fewer procedures being rated inappropriate) by the Dutch panel and more disagreement between panels [41] . Yet, we found the opposite result, the Dutch panel rated more procedures inappropriate than the U.S. panel.
Fifth, American physicians may feel that they are operating in an environment where if there is disagreement on what should be done, the better decision is "to do" and not "to wait" [42] . Dutch physicians, operating under a system of constraints with respect to CABG and PTCA, may base their decision-making more on the available data, which also is what the decision analytic team did.
Finally, the slight agreement between the U.S. panel and the other two groups for CABG and poor agreement for PTCA may be due to the extremely high proportion of cases rated "not inappropriate" by the U.S. panel. When there are extremely skewed ratings, as seen by the small number of cases rated inappropriate by the U.S. panel (see Table 2 ), it is often difficult to achieve greater than chance agreement [19, 20] .
We began this study with the assumption that on theoretical grounds each of the two panels and the decision analysis were an equally valid (if different) way to assess the effectiveness of PTCA and CABG. Given this assumption, the conclusion of our study viewed as a whole is that the different methods have an overall low level of agreement when identifying ineffective PTCA procedures (K = 0.28) and moderate agreement for the identification of ineffective CABG procedures (K = 0.44). This result indicates that there is there is significant agreement above chance and thus there is some evidence that each of these measures is assessing the same concept of effectiveness. In fact, the agreement between the Dutch panel and the decision analysis is quite striking. On an aggregate level these findings provide some support for the use of expert panels or decision analysis to synthesize a body of evidence and measure the effectiveness of care provided by managed care organizations and health care systems. However, for an individual patient these levels of agreement suggest that consistent decisions across methods on whether a procedure should be approved in any kind of pre-certification or utilization review process cannot be made.
The conclusion that the major sources of disagreement occur when any of the methods are extrapolating from sparse data may seem obvious but it has non-trivial implications. It is in precisely these situations that employers and administrators may most wish to use one of these methods for making decisions on what is effective and non-effective care. After all, guidelines are much less difficult to develop when there is abundant evidence. Our results suggest that in this case the conclusion would often depend rather arbitrarily on what method is chosen to assess effectiveness. As governments scrutinize the use of medical technology and invest large sums of money to develop clinical practice guidelines, one should try to assure that guidelines, whether developed by expert panels or decision analysts, are based on more than opinion before deciding which services to support and which to actively discourage.
